Aequus Pharmaceuticals Inc. (AQSZF)
OTCMKTS · Delayed Price · Currency is USD
0.0050
+0.0020 (66.67%)
At close: Jul 10, 2025
Aequus Pharmaceuticals Company Description
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension.
It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Aequus Pharmaceuticals Inc.
| Country | Canada |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Douglas Janzen |
Contact Details
Address: 200 Granville Street Vancouver, British Columbia V6C 1S4 Canada | |
| Phone | 604 336 7906 |
| Website | aequuspharma.ca |
Stock Details
| Ticker Symbol | AQSZF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA0076361033 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas Glen Janzen | Chairman, Chief Executive Officer and President |